Xeris details Phase 3 plan for weekly hypothyroidism therapy XP-8121
Xeris Biopharma Holdings hosted a program overview outlining its Cornerstone trial design and a targeted 2030 approval timeline for XP-8121.
SEC filing
Latest
3 stories
Wednesday, September 9
Thursday, August 6
Xeris reports second-quarter 2026 results, tightens full-year revenue guidance
The company posted 34% year-over-year growth in net product revenue, driven by Recorlev, and narrowed its 2026 revenue outlook to $385 million to $390 million.
SEC filing
Friday, July 17
Xeris completes exchange of 2028 convertible notes, eliminates them from balance sheet
Xeris Biopharma Holdings finished privately negotiated exchanges and a separate conversion of its 8.00% Convertible Senior Notes due 2028, leaving none outstanding as of July 15, 2026.
SEC filing